Stocks · News reference
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pelthos Therapeutics has raised CEO Scott Plesha's base salary and target bonus opportunity while amending his employment agreement to include prorated bonus provisions upon termination.
Pelthos Therapeutics has entered into a definitive agreement to merge with Castle Creek Biosciences, a late-stage gene therapy company, to expand its portfolio into rare skin disease treatments.
Alphatec reported third-quarter 2026 revenue of $221 million, missing analyst expectations, and lowered its full-year 2026 revenue outlook to $862 million.
CareDx stock surged over 22% after reporting strong Q3 2026 earnings with 39% revenue growth to $139 million, driven by a 65% jump in testing services revenue and 51% increase in testing volumes. The company raised its full-year revenue guidance to $525 million (38% growth) and boosted adjusted EBITDA targets to $90-100 million, reflecting growing clinical interest in precision medicine diagnostics.
Alphabet logs its worst week since 2011 and Intel its worst day ever as the AI trade cracks, while health care posts a record month against the market.